Enzymes as modulators in malignant transformation.
Experimental data suggest that sex steroids have a role in the development of breast and prostate cancers. The biological activity of sex steroid hormones in target tissues is regulated by several enzymes, including 17beta-hydroxysteroid dehydrogenases (17HSD). Changes in the expression patterns of these enzymes may significantly modulate the intracellular steroid content and play a pathophysiological role in malignant transformation. To further clarify the role of 17HSDs in breast cancer, we analyzed the mRNA expressions of the 17HSD type 1, 2, and 5 enzymes in 794 breast carcinoma specimens. Both 17HSD type 1 and 2 mRNAs were detected in normal breast tissue from premenopausal women but not in specimens from postmenopausal women. Of the breast cancer specimens, 16% showed signals for 17HSD type 1 mRNA, 25% for type 2, and 65% for type 5. No association between the 17HSD type 1, 2, and 5 expressions was detected. The patients with tumors expressing 17HSD type 1 mRNA or protein had significantly shorter overall and disease-free survival than the other patients. The expression of 17HSD type 5 was significantly higher in breast tumor specimens than in normal tissue. The group with 17HSD type 5 overexpression had a worse prognosis than the other patients. Cox multivariate analyses showed that 17HSD type 1 mRNA, tumor size, and ERalpha had independent prognostic significance. Using an LNCaP prostate cancer cell line, we developed a cell model to study the progression of prostate cancer. In this model, androgen-sensitive LNCaP cells are transformed in culture conditions into more aggressive, androgen-independent cells. The model was used to study androgen and estrogen metabolism during the transformation process. Our results indicate that substantial changes in androgen and estrogen metabolism occur in the cells during the process. A remarkable decrease in oxidative 17HSD activity was seen, whereas reductive activity seemed to increase. Since local steroid metabolism controls the bioavailability of active steroid hormones of target tissues, the variations in steroid-metabolizing enzymes during cancer progression may be crucial in the regulation of the growth and function of organs.
Vihko
P
P
Biocenter Oulu and Research Center for Molecular Endocrinology, University of Oulu, P.O. Box 5000, FI-90014 Oulu, Finland. pirkko.vihko@oulu.fi
Herrala
A
A
Härkönen
P
P
Isomaa
V
V
Kaija
H
H
Kurkela
R
R
Li
Y
Y
Patrikainen
L
L
Pulkka
A
A
Soronen
P
P
Törn
S
S
D015067:17-Hydroxysteroid Dehydrogenases / Q000145:classification / Q000235:genetics / Q000378:metabolism*; D000728:Androgens / Q000378:metabolism; D001943:Breast Neoplasms / Q000201:enzymology / Q000209:etiology / Q000235:genetics; D045744:Cell Line, Tumor; D002471:Cell Transformation, Neoplastic / Q000235:genetics / Q000378:metabolism*; D004967:Estrogens / Q000378:metabolism; D005260:Female; D006801:Humans; D017403:In Situ Hybridization; D008297:Male; D009376:Neoplasms, Hormone-Dependent / Q000201:enzymology / Q000209:etiology / Q000235:genetics; D010084:Oxidation-Reduction; D011471:Prostatic Neoplasms / Q000201:enzymology / Q000209:etiology / Q000235:genetics; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D012334:RNA, Neoplasm / Q000235:genetics / Q000378:metabolism
D000728:Androgens; D004967:Estrogens; D012333:RNA, Messenger; D012334:RNA, Neoplasm; D015067:17-Hydroxysteroid Dehydrogenases